Patents for C12Q 1 - Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions (300,231)
02/2006
02/14/2006US6998473 isolated polynucleotide molecules which encode the isoforms ; methods of screening compounds for vitamin D receptor (VDR) agonists and/or antagonists
02/14/2006US6998472 Obesity gene
02/14/2006US6998263 Methods of preparing and using a viral vector library
02/14/2006US6998261 Functional gene array in yeast
02/14/2006US6998260 DNA expression construct comprising, in 5' to 3' order: a promoter operationally linked to a secretion signal sequence, the secretion signal sequence operationally-linked to a DNA sequence encoding a proteolytic tryptase having active site mutation
02/14/2006US6998254 Use of ROR for receptors for screening substances useful for the treatment of atherosclerosis
02/14/2006US6998250 Detecting the presence of urease in a gastrointestinal system; obtain gastric sample, expose to indicator mixture, evaluate sample for presence of urease
02/14/2006US6998249 conducting at least three distinct assays in parallel to provide information about three distinct parameters of cytotoxicity of a chemical in a given target cell, which information is useful for predicting in vivo cytotoxicity
02/14/2006US6998248 a porous matrix; an analyte oxidation signal producing system; an hemolyzing agent for producing hemosylate in the sample, at least one of: (i) a means for obtaining the physiological sample; and (ii) an analyte standard
02/14/2006US6998247 Use of an alternative invasive or noninvasive glucose determination in the calibration allows minimization of errors due to sampling methodology, and spatial and temporal variation that are built into the calibration model
02/14/2006US6998244 contacting a cell transformed or transfected with an expression vector capable of expressing 5-HT4 receptor with a compound in presence of a ligand, monitoring CAMP formation in the cell, a change indicates compund as an antagonist or agonist
02/14/2006US6998239 contacting an isolated or recombinant CCX CKR polypeptide or, a fragment or variant, and the chemokine in the presence of a test compound, comparing the level of binding of the chemokine and the polypeptide
02/14/2006US6998237 GD3 peptide mimics
02/14/2006US6998236 Methods for detecting interaction between a test moiety and a plurality of target moieties
02/14/2006US6998235 Method of determining susceptibility to bipolar disorders
02/14/2006US6998234 Determining gene expression profile of vascular endothelial cells; obtain cells, incubate with immunological agent, isolate bound cells, extract ribonucleic acid sequences, expose to probe, monitor expression profile
02/14/2006US6998233 Methods for ligand discovery
02/14/2006US6998232 determining, in a sample from a human subject, the level of expression of at least two polynucleotides, wherein a higher level of expression of the polynucleotides compared to cancer free human polynucleotide expression is an indication of cancer
02/14/2006US6998231 Coding or classification of prion sample; obtain sample, monitor physical properties of sample, compare to control
02/14/2006US6998230 A computer program products using the drop deposition apparatus, for fabricating at least one addressable array of biopolymers on a substrate; useful in diagnostic, screening, gene expression analysis
02/14/2006US6998229 Used to control expression of a transgene, detect glucuronides in a sample, and isolate glucuronides from a sample
02/14/2006US6998228 Generation of solid support for use in the detection of preferential targets in sample; obtain surface, deposit preferential material on surface, form support
02/14/2006US6998055 Concentration device using magnetic particles and method therefor
02/14/2006US6998042 Solid compositions for selective adsorption from complex mixtures
02/14/2006US6997963 Use of a chromoionophore and/or fluoroionophore for dyeing human keratin fibres, dyeing compositions and methods
02/14/2006CA2384170C Cgmp-visualizing probe and method of detecting and quantifying cgmp by using the same
02/14/2006CA2286195C Method and devices for partitioning biological sample liquids into microvolumes
02/14/2006CA2269072C Vascular endothelial growth factor (vegf) nucleic acid ligand complexes
02/14/2006CA2251850C Water-soluble tetrazolium salt compounds
02/14/2006CA2198470C Luciferase labelling method
02/09/2006WO2006015389A2 Methods and compositions for enhancing the efficacy and specificity of rna silencing
02/09/2006WO2006015374A2 Compositions and methods for preparation of nucleic acids from microbial samples
02/09/2006WO2006015369A2 Assays for identification of topoisomerase inhibitors
02/09/2006WO2006015326A2 Methods of isolating nucleic acids using multifunctional group-coated solid phase carriers
02/09/2006WO2006015308A2 Modular microfluidic packaging system
02/09/2006WO2006015190A2 Methods of screening for antitumor agents
02/09/2006WO2006015114A2 Imaging methods and apparatus having extended dynamic range
02/09/2006WO2006015084A2 Compositions, kits and assays containing reagents directed to cortactin and an arg/abl protein kinase
02/09/2006WO2006015056A2 Enhancing flow cytometry discrimination with geometric transformation
02/09/2006WO2006015047A2 Differential expression of genes in microsatellite instability
02/09/2006WO2006014958A2 Platelet activation markers as predictors of disease and of response to therapy and for monitoring therapeutic progress
02/09/2006WO2006014903A2 Compositions and methods of use for adam12 antagonists in treating disease
02/09/2006WO2006014869A1 Simultaneous analysis of multiple genomes
02/09/2006WO2006014755A2 Methods of identifying patients at risk of developing encephalitis following immunotherapy for alzheimer’s disease
02/09/2006WO2006014644A2 Method and system for generating a telephone alert
02/09/2006WO2006014639A2 Sequencing of modified nucleic acid molecules
02/09/2006WO2006014588A2 Nucleic acid end-labeling reagents
02/09/2006WO2006014559A2 Cyclic peptides for treatment of cachexia
02/09/2006WO2006014530A2 Imaging of enzyme activity
02/09/2006WO2006014509A2 Quantitative pcr data analysis system (qdas)
02/09/2006WO2006014464A2 Method for quantitative pcr data analysis system (qdas)
02/09/2006WO2006014424A2 Methods and compositions for detecting and isolating phosphorylated molecules using hydrated metal oxides
02/09/2006WO2006014422A2 Polynucleotide encoding a trim-cyp polypeptide, compositions thereof, and methods of using same
02/09/2006WO2006014351A2 Exploring fluorophore microenvironments
02/09/2006WO2006014335A2 Compositions and methods for treatment of non-hodgkin’s lymphoma
02/09/2006WO2006014232A2 Dengue protease substrates and inhibitors
02/09/2006WO2006014218A2 Treatment or prevention of cancer or cardiovascular disease with methenyltetrahydrofolate synthetases
02/09/2006WO2006014109A1 Neisseria gonorrhoeae detection using the 5′ untranslated region of the opa gene
02/09/2006WO2006014022A1 Instrument for detecting bacterium, method of detecting bacterium and kit for detecting bacterium
02/09/2006WO2006013921A1 Reagent containing protease reaction promoter and/or colorant stabilizer
02/09/2006WO2006013561A2 Compositions and methods for diagnosing and treating post traumatic stress disorder
02/09/2006WO2006013474A2 Ppgalnac-t6 mrna or peptide as a new marker for detection cancer cells
02/09/2006WO2006013388A2 Materials and methods for modulating signalling by alpha-v integrin molecules
02/09/2006WO2006013144A2 Method of in-vitro detection and quantification of hiv dna by quantitative pcr
02/09/2006WO2006013110A1 Parallel high throughput single molecule sequencing process
02/09/2006WO2006013078A2 Method and kit for microbiologically identifying vitamins in substance mixtures
02/09/2006WO2006013072A2 Method for isolation of transcription termination sequences
02/09/2006WO2006013016A2 Diagnostics and therapeutics for diseases associated with eosinophil serine protease 1 (prss21)
02/09/2006WO2006013015A2 Diagnostics and therapeutics for diseases associated with marapsin (mpn)
02/09/2006WO2006013013A2 Diagnostics and therapeutics for diseases associated with protective protein for beta-galactosidase (ppgb)
02/09/2006WO2006013003A1 Use of products derived from selenoprotein t, in its application related to calcium homeostasis
02/09/2006WO2005118885A3 Methods and apparatus for detection of viral infection
02/09/2006WO2005118864A3 Antibodies and related molecules that bind to psca proteins
02/09/2006WO2005113786A3 Diagnostics and therapeutics for diseases associated with chymase (cma1)
02/09/2006WO2005110479A3 Treatments for pancreatic cancer
02/09/2006WO2005108617A3 Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
02/09/2006WO2005103302A3 Mutant viral nucleic acids and vaccine containing same
02/09/2006WO2005103285A3 Systems and methods for indicating oxidation of consumer products
02/09/2006WO2005098037A8 Breast cancer signatures
02/09/2006WO2005093425A3 Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 58 (gpr58)
02/09/2006WO2005093423A3 Diagnostics and therapeutics for diseases associated with peroxisome proliferative activated receptor alpha (ppara)
02/09/2006WO2005090993A3 Diagnostics and therapeutics for diseases associated with lung seven transmembrane receptor 1 (lustr1)
02/09/2006WO2005086896A3 Delivery vectors for short interfering rna, micro-rna and antisense rna
02/09/2006WO2005080594A3 Method for determining the risk of developing a neurological disease
02/09/2006WO2005074646A3 Methods and systems for joint analysis or array cgh data and gene expression data
02/09/2006WO2005074467A3 Matrix array nanobiosensor
02/09/2006WO2005073400A3 Method of identifying amp- activated protein kinase (ampk) modulators and uses therefor
02/09/2006WO2005070044A3 Systems and methods for short rna expression
02/09/2006WO2005068663A3 Methods of using peroxisome proliferator-activated receptor alpha target genes
02/09/2006WO2005067643A3 Determination of hepatitis c virus genotype
02/09/2006WO2005059779A3 Indexing scheme for formulation workflows
02/09/2006WO2005050223A3 Proteome epitope tags and methods of use thereof in protein modification analysis
02/09/2006WO2005036126A3 Apparatus and methods for fluorescent detection of nucleic acids
02/09/2006WO2005030041A3 Detection of hpv
02/09/2006WO2005026686A3 Multiplexed analytical platform
02/09/2006WO2005000087A3 Gene products differentially expressed in cancerous colon cells and their methods of use ii
02/09/2006WO2004088274A3 Psychoactive compound associated markers and method of use thereof
02/09/2006WO2004056983A3 Metalloprotease proteins
02/09/2006WO2004050839A3 Fragmentation-based methods and systems for sequence variation detection and discovery
02/09/2006WO2004028478A3 Functional mutations in respiratory syncytial virus